| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...619399L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0019399 |
| P932 | PMC publication ID | 3084844 |
| P698 | PubMed publication ID | 21559362 |
| P5875 | ResearchGate publication ID | 51114430 |
| P50 | author | Patrick C Y Woo | Q89296982 |
| P2093 | author name string | Ling Li | |
| Qi Wang | |||
| Zhi Chen | |||
| Cui Hua Liu | |||
| Baoli Zhu | |||
| Yong Liang Hu | |||
| P2860 | cites work | Progress in tuberculosis control and the evolving public-health system in China | Q50908835 |
| HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality | Q84734382 | ||
| Extensively drug-resistant tuberculosis | Q28238036 | ||
| The effect of tuberculosis control in China | Q28275199 | ||
| Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study | Q28303675 | ||
| Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures | Q28469334 | ||
| Management of extensively drug-resistant tuberculosis in Peru: cure is possible | Q28473393 | ||
| Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment | Q28474035 | ||
| Transmission of MDR and XDR tuberculosis in Shanghai, China | Q28474677 | ||
| Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis | Q28476110 | ||
| Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia | Q34108995 | ||
| Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. | Q34974467 | ||
| Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. | Q36170956 | ||
| Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment | Q36959143 | ||
| Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000-2006. | Q37015561 | ||
| Multidrug- and extensively drug-resistant tuberculosis, Germany | Q37072346 | ||
| Extensively drug-resistant tuberculosis: current challenges and threats | Q37163527 | ||
| Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis | Q37216059 | ||
| Multidrug-resistant and extensively drug-resistant tuberculosis: a review | Q37315209 | ||
| Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance | Q37449352 | ||
| Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis | Q38429617 | ||
| Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. | Q39870761 | ||
| Barriers to TB care for rural-to-urban migrant TB patients in Shanghai: a qualitative study | Q39882496 | ||
| Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study | Q43058124 | ||
| Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? | Q44312351 | ||
| Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis | Q45126482 | ||
| Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. | Q45126969 | ||
| Extensively drug-resistant tuberculosis in the United States, 1993-2007. | Q46252876 | ||
| Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan | Q46420649 | ||
| Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital | Q46826206 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Beijing | Q956 |
| patient | Q181600 | ||
| tuberculosis | Q12204 | ||
| P304 | page(s) | e19399 | |
| P577 | publication date | 2011-04-29 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience | |
| P478 | volume | 6 |
| Q53172300 | Antibacterial Effects of Liposomes Containing Phospholipid Cardiolipin and Fluoroquinolone Levofloxacin on Mycobacterium tuberculosis with Extensive Drug Resistance |
| Q37345726 | Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program |
| Q86505583 | Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China |
| Q53041364 | Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis |
| Q55208580 | Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. |
| Q33805218 | Comparative genomic analysis of Mycobacterium tuberculosis clinical isolates |
| Q36211805 | Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China |
| Q28544800 | Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK |
| Q42211847 | Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis |
| Q58750099 | Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria |
| Q38718198 | Efficacy and effect of free treatment on multidrug-resistant tuberculosis |
| Q38644773 | Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China |
| Q57488988 | Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot |
| Q41376759 | Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management |
| Q26830094 | Extensively drug-resistant tuberculosis: epidemiology and management |
| Q38867253 | Factors associated with mortality in tuberculosis patients |
| Q38545953 | Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis |
| Q36260334 | Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. |
| Q47748869 | Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method |
| Q33889335 | Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates |
| Q34467936 | Longer hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan Africa |
| Q28544642 | Loss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa |
| Q28547002 | Map the gap: missing children with drug-resistant tuberculosis |
| Q28543698 | Molecular epidemiology and clinical characteristics of drug-resistant Mycobacterium tuberculosis in a tuberculosis referral hospital in China |
| Q55424020 | Mortality and associated factors of patients with extensive drug-resistant tuberculosis: an emerging public health crisis in China. |
| Q36257425 | Reasons for Non-Enrollment in Treatment among Multi-Drug Resistant Tuberculosis Patients in Hunan Province, China |
| Q43607612 | Risk factors associated with kanamycin-resistant tuberculosis in a Beijing tuberculosis referral hospital |
| Q28536653 | Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation |
| Q27681391 | Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors |
| Q33811760 | The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership. |
| Q36252929 | Transmission of Extensively Drug-Resistant Tuberculosis in South Africa |
| Q57922788 | Treatment Outcomes Associated with Multidrug-resistant Tuberculosis |
| Q33561777 | Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis |
| Q36825990 | Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection |
| Q38621696 | Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China |
| Q52594133 | Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement |
Search more.